The Anti-Thrombotic Effects of PCSK9 Inhibitors
Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/9/1197 |
| _version_ | 1797578129723621376 |
|---|---|
| author | Martin Jozef Péč Jakub Benko Jakub Jurica Monika Péčová Marek Samec Tatiana Hurtová Tomáš Bolek Peter Galajda Martin Péč Matej Samoš Marián Mokáň |
| author_facet | Martin Jozef Péč Jakub Benko Jakub Jurica Monika Péčová Marek Samec Tatiana Hurtová Tomáš Bolek Peter Galajda Martin Péč Matej Samoš Marián Mokáň |
| author_sort | Martin Jozef Péč |
| collection | DOAJ |
| description | Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of many patients in recent years. Their inhibitory effect on atherosclerosis progression seems to be driven not just by lipid metabolism modification but also by LDL-independent mechanisms. We review the effect of PCSK9 inhibitors on various mechanisms involving platelet activation, inflammation, endothelial dysfunction, and the resultant clot formation. The main effectors of PCSK9 activation of platelets are CD36 receptors, lipoprotein(a), oxidised LDL particles, tissue factor, and factor VIII. Many more molecules are under investigation, and this area of research is growing rapidly. |
| first_indexed | 2024-03-10T22:17:54Z |
| format | Article |
| id | doaj.art-e3be53e14e314decb53aaa481c828657 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T22:17:54Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-e3be53e14e314decb53aaa481c8286572023-11-19T12:23:53ZengMDPI AGPharmaceuticals1424-82472023-08-01169119710.3390/ph16091197The Anti-Thrombotic Effects of PCSK9 InhibitorsMartin Jozef Péč0Jakub Benko1Jakub Jurica2Monika Péčová3Marek Samec4Tatiana Hurtová5Tomáš Bolek6Peter Galajda7Martin Péč8Matej Samoš9Marián Mokáň10Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaOncology Centre, Teaching Hospital Martin, 036 59 Martin, SlovakiaDepartment of Pathological Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Infectology and Travel Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Medical Biology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaAtherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of many patients in recent years. Their inhibitory effect on atherosclerosis progression seems to be driven not just by lipid metabolism modification but also by LDL-independent mechanisms. We review the effect of PCSK9 inhibitors on various mechanisms involving platelet activation, inflammation, endothelial dysfunction, and the resultant clot formation. The main effectors of PCSK9 activation of platelets are CD36 receptors, lipoprotein(a), oxidised LDL particles, tissue factor, and factor VIII. Many more molecules are under investigation, and this area of research is growing rapidly.https://www.mdpi.com/1424-8247/16/9/1197LDLlipoprotein aplatelet activationthrombus |
| spellingShingle | Martin Jozef Péč Jakub Benko Jakub Jurica Monika Péčová Marek Samec Tatiana Hurtová Tomáš Bolek Peter Galajda Martin Péč Matej Samoš Marián Mokáň The Anti-Thrombotic Effects of PCSK9 Inhibitors Pharmaceuticals LDL lipoprotein a platelet activation thrombus |
| title | The Anti-Thrombotic Effects of PCSK9 Inhibitors |
| title_full | The Anti-Thrombotic Effects of PCSK9 Inhibitors |
| title_fullStr | The Anti-Thrombotic Effects of PCSK9 Inhibitors |
| title_full_unstemmed | The Anti-Thrombotic Effects of PCSK9 Inhibitors |
| title_short | The Anti-Thrombotic Effects of PCSK9 Inhibitors |
| title_sort | anti thrombotic effects of pcsk9 inhibitors |
| topic | LDL lipoprotein a platelet activation thrombus |
| url | https://www.mdpi.com/1424-8247/16/9/1197 |
| work_keys_str_mv | AT martinjozefpec theantithromboticeffectsofpcsk9inhibitors AT jakubbenko theantithromboticeffectsofpcsk9inhibitors AT jakubjurica theantithromboticeffectsofpcsk9inhibitors AT monikapecova theantithromboticeffectsofpcsk9inhibitors AT mareksamec theantithromboticeffectsofpcsk9inhibitors AT tatianahurtova theantithromboticeffectsofpcsk9inhibitors AT tomasbolek theantithromboticeffectsofpcsk9inhibitors AT petergalajda theantithromboticeffectsofpcsk9inhibitors AT martinpec theantithromboticeffectsofpcsk9inhibitors AT matejsamos theantithromboticeffectsofpcsk9inhibitors AT marianmokan theantithromboticeffectsofpcsk9inhibitors AT martinjozefpec antithromboticeffectsofpcsk9inhibitors AT jakubbenko antithromboticeffectsofpcsk9inhibitors AT jakubjurica antithromboticeffectsofpcsk9inhibitors AT monikapecova antithromboticeffectsofpcsk9inhibitors AT mareksamec antithromboticeffectsofpcsk9inhibitors AT tatianahurtova antithromboticeffectsofpcsk9inhibitors AT tomasbolek antithromboticeffectsofpcsk9inhibitors AT petergalajda antithromboticeffectsofpcsk9inhibitors AT martinpec antithromboticeffectsofpcsk9inhibitors AT matejsamos antithromboticeffectsofpcsk9inhibitors AT marianmokan antithromboticeffectsofpcsk9inhibitors |